Science Explorer Back to mapMap

Most cited papers from Highlight Therapeutics (Spain)

What are the most cited papers from Highlight Therapeutics (Spain)?

The most cited paper from Highlight Therapeutics (Spain) is "Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)" (Aurélien Marabelle et al., 2018), with 216 citations. Next come "Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44" (145) and "Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma" (138).

Showing 39 of 39 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) Aurélien Marabelle et al. · Annals of Oncology Open access 6 Oct 2018 216
2 Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44 Alice Spadea, Julio M. Rios De La Rosa, Annalisa Tirella et al. · Molecular Pharmaceutics 23 Apr 2019 145
3 Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma Anusha K. Kalbasi, Mito Tariveranmoshabad, Kevin N. Hakimi et al. · Science Translational Medicine Open access 14 Oct 2020 138
4 Immunotherapeutic effects of intratumoral nanoplexed poly I:C Maria Angela Aznar, Lourdes Planelles, Mercedes Pérez‐Olivares et al. · Journal for ImmunoTherapy of Cancer Open access 2 May 2019 134
5 Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells Clara Gomez‐Aleza et al. · Nature Communications Open access 10 Dec 2020 93
6 Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors Iván Márquez‐Rodas et al. · Science Translational Medicine 14 Oct 2020 86
7 Rational optimization of a transcription factor activation domain inhibitor Shaon Basu et al. · Nature Structural & Molecular Biology Open access Dec 2023 78
8 Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy Maite Álvarez, Carmen Fernandez Molina, Carlos E. de Andrea et al. · Journal for ImmunoTherapy of Cancer Open access Nov 2021 42
9 Mobile integrons encode phage defense systems Nicolas Kieffer, Alberto Hipólito, Laura Ortiz-Miravalles et al. · Science Open access 8 May 2025 36
10 Intravitreal Injection of Proinsulin-Loaded Microspheres Delays Photoreceptor Cell Death and Vision Loss in therd10Mouse Model of Retinitis Pigmentosa Carolina Isiegas, Jorge A. Marinich-Madzarevich, Miguel Marchena et al. · Investigative Ophthalmology & Visual Science Open access 8 Jul 2016 28
11 Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control Maria Esperanza Rodriguez-Ruiz, Irantzu Serrano-Mendioroz, Eneko Garate-Soraluze et al. · Journal for ImmunoTherapy of Cancer Open access 2023 25
12 Composite resin inlays: a study of marginal adaptation. Carmen Llena, L Forner Navarro, Faus Llacer Vj et al. · PubMed Jun 1993 25
13 Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic Maite Álvarez, Carmen Fernandez Molina, Saray Garasa et al. · OncoImmunology Open access 5 Apr 2023 14
14 BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203 Iván Márquez‐Rodas et al. · Journal of Clinical Oncology Open access 27 Jun 2025 13
15 Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors Iván Márquez‐Rodas, Federico Longo, Maria Esperanza Rodriguez-Ruiz et al. · Annals of Oncology Open access Oct 2018 12
16 Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C Celia Gomar, Claudia Augusta Di Trani, Ángela Bella et al. · Journal for ImmunoTherapy of Cancer Open access Apr 2024 8
17 961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy Iván Márquez‐Rodas et al. Conference paperOpen access Nov 2021 8
18 Evaluation of the potential therapeutic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of endometriosis Carmen María García-Pascual, Jessica Martínez, Paula Calvo et al. · Fertility and Sterility Open access 18 Aug 2015 8
19 ZebraReg—a novel platform for discovering regulators of cardiac regeneration using zebrafish Kateřina Apolínová, Ferran Arqué Pérez, Sylvia Dyballa et al. · Frontiers in Cell and Developmental Biology Open access 10 May 2024 7
20 A Phase 1 randomized study on the safety and pharmacokinetics of OCS-05, a neuroprotective disease modifying treatment for Acute Optic Neuritis and Multiple Sclerosis Pablo Villoslada, Mar Masso, Stéphane Paris et al. · Scientific Reports Open access 29 Mar 2023 7
21 In vivo genome editing of human hematopoietic stem cells for treatment of blood disorders by mRNA delivery Saijuan Xu, Dan Liang, Qiudao Wang et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access Nov 2024 6
22 In vivo photocontrol of orexin receptors with a nanomolar light-regulated analogue of orexin-B Davia Prischich, Rosalba Sortino, Alexandre M. J. Gomila et al. · Cellular and Molecular Life Sciences Open access 6 Jul 2024 6
23 Evaluation of the antiproliferative, proapoptotic, and antiangiogenic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of leiomyoma Carmen María García-Pascual, Hortensia Ferrero, Irene Juarez et al. · Fertility and Sterility Open access 24 Nov 2015 4
24 GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH María Andrés‐Rozas, Zoe Boyer‐Díaz, Eugènia Ruiz-Cánovas et al. · JHEP Reports Open access 15 Jul 2025 3
25 GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in models of Parkinson’s disease Blanca Erika Gutiérrez-Guzmán, N. Gómez Pérez, Ana María García et al. · Parkinsonism & Related Disorders Aug 2023 3
26 Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial Iván Márquez‐Rodas, Marta Ester Ruíz, S. Lopez-Tarruella Cobo et al. · Annals of Oncology Open access Sep 2017 3
27 Mesothelioma, a Review of Current Guidelines Sonia Maciá · IntechOpen eBooks Book chapterOpen access 17 Sep 2020 2
28 Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer Iván Márquez‐Rodas, Federico Longo, Santiago Ponce Aix et al. · Annals of Oncology Open access Dec 2019 2
29 Bayesian model of disease progression in mucopolysaccaridosis IIIA Joe Marion, Juan Manuel Garcı́a-Ruiz, Benjamin R. Saville · Statistics in Medicine 13 May 2022 1
30 Interim results of Transpher A, a multicentre, single-dose, phase 1/2 clinical trial of ABO-102 investigational gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA) Kevin M. Flanigan, Nicholas J.N. Smith, María Luz Couce et al. · Molecular Genetics and Metabolism Feb 2022 1
31 Hyaluronic acid carrier-cell interactions: a tri-culture model of the tumour microenvironment to study siRNA delivery under flow conditions Julio M. Rios De La Rosa, Nicola Tirelli, Annalisa Tirella · International Journal of Nano and Biomaterials Open access 2019 1
32 Cross-immunity to therapeutic Kayvirus staphylophages reveals conserved immunogenic epitopes in patients Mireia Bernabéu-Gimeno, Alonso Felipe-Ruíz, Pilar García et al. · Clinical Microbiology and Infection Apr 2026 0
33 Predictors of clinical and pathological response in patients with basal cell carcinoma treated with BO-112, a novel intralesional treatment J. Cañueto, A. Toll Abelló, D. Egozi et al. · EJC Skin Cancer Open access 2026 0
34 Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results J. Deng et al. · Cancer Discovery Open access 5 Mar 2026 0
35 Intratumoral dsRNA Sensor Activation Redirects Radiation-Associated Myeloid Cells to Ignite Local and Systemic Anti-Tumor Immunity in Undifferentiated Pleomorphic Sarcoma Jun Deng, S. Chin, Mito Tariveranmoshabad et al. · International Journal of Radiation Oncology*Biology*Physics 22 Oct 2022 0
36 Hyaluronic acid carrier-cell interactions: a tri-culture model of the tumour microenvironment to study siRNA delivery under flow conditions Annalisa Tirella, Julio M. Rios De La Rosa, Nicola Tirelli · International Journal of Nano and Biomaterials 2019 0
37 Satisfaction with grass pollen sublingual immunotherapy assessed by ESPIA questionnaire – first results from Bulgaria Plamena Ivanova Novakova, José Luis Justicia, Maria Toncheva Staevska et al. · World Allergy Organization Journal Open access Aug 2020 0
38 Brain penetrant structurally targeted allosteric regulators for treating GLB1-related disorders Manolo Bellotto, Roberto Maj, Ana María García-Collazo et al. · Molecular Genetics and Metabolism 30 Jan 2020 0
39 BO-110, a dsRNA-Based Anticancer Agent Mercedes Pozuelo-Rubio, Damiá Tormo Carulla, Andrés P. Gagete et al. · Advances in delivery science and technology Book chapter 2014 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.